<DOC>
	<DOCNO>NCT00914524</DOCNO>
	<brief_summary>The treatment period 16 week , initial dose , 5 mg , unforcedly titrate 10 mg , 20 mg 40 mg confirm tolerance week 4 , 8 12 . The primary endpoint efficacy change urinary protein/creatinine ratio baseline end treatment . The secondary endpoint creatinine clearance ( Ccr ) .</brief_summary>
	<brief_title>Study Olmesartan Medoxomil ( CS-866 ) Patients With Chronic Glomerulonephritis Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>urinary protein/creatinine ratio 0.50 g/g 3.50 g/g creatinine range normal sit blood pressure value : systolic blood pressure 100 mmHg 140 mmHg ; diastolic blood pressure 50 mmHg less 90 mmHg treatment corticosteroid immunosuppressant treatment antihypertensive ( ARBs ACE inhibitor ) serum potassium level 5.5 mEq/l serum creatinine level 2.0 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Chronic Glomerulonephritis</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Angiotensin II Receptor Blocker</keyword>
	<keyword>Urinary Protein</keyword>
</DOC>